Other languages Baudax Bio, Inc.

Equities

Market Closed - OTC Markets Other stock markets 20:39:06 25/06/2024 BST			5-day change	1st Jan Change
0.008 ^USD	+23.08%		+6.67%	-63.64%

06-17	First Motion for Exclusivity Period Extension Filed by Baudax Bio, Inc.	CI
02-22	Baudax Bio, Inc. Filed for Bankruptcy	CI

First Motion for Exclusivity Period Extension Filed by Baudax Bio, Inc.	06-17
Baudax Bio, Inc. Filed for Bankruptcy	02-22
Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20
Baudax Bio, Inc. to Initiate TI-168 Clinical Development	18/10/23
Sector Update: Health Care Stocks Advancing in Late Afternoon Trading	06/10/23
Sector Update: Health Care Stocks Higher in Afternoon Trading	06/10/23
Baudax Bio Appoints Natalie McAndrew as Interim Finance Chief	06/10/23
Baudax Bio, Inc. Announces Board Changes	06/10/23
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	29/09/23
Top Premarket Decliners	29/09/23
Baudax Bio, Inc. Announces Orphan Drug Designation Granted by U.S. Fda for Ti-168 for the Treatment of Hemophilia A with Inhibitors	29/09/23
Sector Update: Health Care Stocks Rising in Late Afternoon Trading	28/09/23
Sector Update: Health Care	28/09/23
Top Midday Gainers	28/09/23
Wall Street Set to Open Flat; Q2 GDP Rises 2.1%; Jobless Claims Lower Than Expected	28/09/23
Baudax Bio Files Registration Statement on Behalf of Selling Stockholder	22/09/23
Baudax Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	16/08/23
Baudax Bio, Inc. Appoints Yong Chan Kim as A Member of the Board	05/07/23
Sector Update: Health Care Stocks Advancing in Late Trading	30/06/23
Sector Update: Health Care	30/06/23

No results for this search